SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr. Reddy's Laboratories reports 83% fall in Q4 consolidated net profit

19 May 2022 Evaluate

Dr. Reddy's Laboratories has reported results for fourth quarter and year ended March 31, 2022.

The company has reported a rise of 34.74% in its net profit at Rs 419.70 crore for the quarter under review as compared to Rs 311.50 crore for the same quarter in the previous year. Total income of the company increased by 10.23% at Rs 3783.40 crore for Q4FY22 as compared Rs 3432.30 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported a fall of 82.59% in its net profit at Rs 97 crore for the quarter under review as compared to Rs 557.30 crore for the same quarter in the previous year. However, total income of the company increased by 15.38% at Rs 5596.80 crore for Q4FY22 as compared Rs 4850.80 crore for the corresponding quarter previous year.

For the year ended March 31, 2022, the company has reported fall of 25.76% in its net profit at Rs 1623.20 crore as compared to Rs 2186.40 crore for the previous year. However, total income of the company increased by 5.21% at Rs 14887.20 crore for year under review as compared to Rs 14150.20 crore for year ended March 31, 2021.

For the year ended March 31, 2022, on the consolidated basis, the company has reported a rise of 11.83% in its net profit at Rs 2182.50 crore as compared to Rs 1951.60 crore for the previous year. Total income of the company increased by 13.91% at Rs 22029.60 crore for year under review as compared to Rs 19338.90 crore for year ended March 31, 2021.

Dr. Reddys Labs. Share Price

1385.00 35.00 (2.59%)
29-Jun-2026 13:39 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1875.00
Dr. Reddys Labs. 1385.00
Cipla 1468.05
Zydus Lifesciences 1114.05
Lupin 2377.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: